Article Text

Download PDFPDF
Atomoxetine: a new pharmacotherapeutic approach in the management of attention deficit/hyperactivity disorder
  1. J Barton
  1. Correspondence to:
    Dr J Barton
    North Staffordshire Combined Health Care NHS Trust, Moorlands Team, Abbey Hulton Clinic, Leek Road, Stoke-On-Trent, Staffordshire ST2 8BP, UK;


Atomoxetine is a novel, non-stimulant, highly selective noradrenaline reuptake inhibitor that has been studied for use in the treatment of attention deficit/hyperactivity disorder (ADHD). Data from clinical trials show it to be well tolerated and effective in the treatment of ADHD in children, adolescents, and adults. Improvements were seen not only in core symptoms of ADHD, but also in broader social and family functioning and self esteem. Once-daily dosing of atomoxetine has been shown to be effective in providing continuous symptom relief. Atomoxetine does not appear to have abuse potential and is associated with a benign side effect profile. The development of atomoxetine thus represents an important advance in the pharmacological management of ADHD.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles

  • Editorial
    P Hill